Lynx Investment Advisory Cytokinetics Inc Transaction History
Lynx Investment Advisory
- $135 Billion
- Q2 2024
A detailed history of Lynx Investment Advisory transactions in Cytokinetics Inc stock. As of the latest transaction made, Lynx Investment Advisory holds 250 shares of CYTK stock, worth $14,040. This represents 0.01% of its overall portfolio holdings.
Number of Shares
250Holding current value
$14,040% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
406Shares Held
126MCall Options Held
3.29MPut Options Held
2.01M-
Black Rock Inc. New York, NY14.7MShares$824 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$642 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.14MShares$457 Million0.28% of portfolio
-
Wellington Management Group LLP Boston, MA7.51MShares$422 Million0.07% of portfolio
-
State Street Corp Boston, MA6.55MShares$368 Million0.02% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.29B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...